Arthur from United Kingdom

Registered at the short selling broker StormGain, 4 minutes ago.

» Try StormGain you too
There is no percentage of traders loosing on crypto platforms.
Don't show again

GlaxoSmithKline Plc (GSK) shares information

Glaxosmithkline plc – ADR

24h Change

0.25 %


Live rate: Market closed

Stock data per Wednesday 14 Apr, 2021

0.09 (+ 0.25%)
US Market is closed

Live Stock price in graph for Glaxosmithkline plc – ADR (GSK)

  • Latest Volume

    4,279,932 (29.68 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    36.32 USD

  • Today low

    35.983 USD

  • 52 week high

    41.01 USD

  • 52 week low

    32.26 USD

  • YTD Change

    + 0.18 %

Quick links


Latest news about Glaxosmithkline plc – ADR

Below you can find the most recent news posts about Glaxosmithkline plc – ADR, primarily from US and UK based news sources.

Americans might start getting a third booster shoot for Moderna vaccines this year (MRNA)

Wednesday, 14 April 2021, 16:01:40
Summary List Placement COVID-19 vaccine shots aren't stopping anytime soon. Moderna announced Americans could start getting booster shots to protect against variant strains later this year. “It is likely that the countries that have already achieved high vaccine coverage are going to be ready to shift their focus to boosters in 2022, and possibly even starting at the end of this year,” Corinne M. Le Goff, Moderna chief commercial officer, said during a call with investors on Wednesday. Le Goff said countries like the US that have succeeded in quickly inoculating their populations will start getting booster shots as soon as possible. But because just 5% of the global population has been vaccinated so far, most countries will continue giving residents the initial shots. Read more: GlaxoSmithKline stumbled with COVID-19 shots. Now it's facing an exodus of US talent and an uncertain future as the world's vaccine leader. The US has administered more than 85 million Moderna COVID-19 vaccines as of mid-April.
— Business Insider

British pharmaceuticals giant to ‘fill and finish' Novavax Covid vaccines amid threat of jabs trade war

Monday, 29 March 2021, 18:55:00
Sixty million doses will be finished at GlaxoSmithKline's Barnard Castle factory in the North East to avoid transportation to Europe
— The Telegraph

GlaxoSmithKline Will Help Manufacture Novavax’s Covid-19 Vaccine for U.K.

Monday, 29 March 2021, 18:53:00
The big pharma firm (GSK)disclosed the latest in a recent spate of Covid-19 vaccine manufacturing collaborations, saying it would help make up to 60 million doses of (NVAX)’s vaccine for use in the U.K. (GSK) (ticker: GSK) said Monday it will be providing fill and finish capacity, the last step in the vaccine manufacturing process, at one of its facilities in England. The vaccine antigen itself will be made by a (NVAX) partner called FUJIFILM Diosynth Biotechnologies at another factory in England.
— Yahoo Finance

GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

Friday, 26 March 2021, 17:42:51
GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc. (NASDAQ: VIR ) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition. What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses. The preclinical data suggests VIR-7831 could potentially block viral entry into healthy … Full story available on
— Benzinga

Booming CAGR of 14.4%, Monoclonal Antibodies Market to Surpass US$ 368.8 Billion by 2027 | Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc

Tuesday, 23 March 2021, 12:16:11
A new market study on the 2020-2027 Monoclonal Antibody Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents
— OpenPR

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have GSK available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.